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Abstract
Background: Cervical cancer is the third largest cause of cancer mortality in India. The objectives of the study were to
compare the pre and the post treatment quality of life in cervical cancer patients and to develop a prediction model to
provide an insight into the possibilities in the treatment modules.
Methodology/Principal Findings: A total of 198 patients were assessed with two structured questionnaires of Health
Related Quality of Life (The European Organisation for Research and Treatment of Cancer, EORTC QLQ C-30 and CX-24). The
baseline observations were recorded when the patients first reported (T1) and second evaluation was done at 6 months
post treatment (T2). The mean age of detection was 50.9 years with the literacy level being non-educated or less than high
school. Majority of them were married/cohabiting 179 (90.4%). On histopathological examination (HPE) squamous cell
carcinoma was found to be the most common cell type carcinoma 147 (74.2%) followed by Adenocarcinoma 31 (15.7%).
Radical hysterectomy was the most common treatment modality 76 (38.4%), followed by Wertheims Hysterectomy 46
(23.2%) and Radiochemotherapy 59 (29.8%). The mean score of global health of cervical cancer patients post treatment was
77.90, which was significantly higher than the pre - treatment score (54.32). Mean ‘‘symptoms score’’ post treatment was
21.69 with an aggravation of 7.32 compared to pre treatment scores. Patients experienced substantial decrease in sexual
activity post treatment.
Conclusions/Significance: The prediction model(PrediQt-Cx), based on Support Vector Machine(SVM) for predicting post
treatment HRQoL in cervical cancer patients was developed and internally cross validated. After external validation PrediQt-
Cx can be easily employed to support decision making by clinicians and patients from north India region, through openly
made available for access at http://prediqt.org.
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Introduction
Background
Cervical cancer is one of the most common cancers worldwide
[1]. The disparity between the mortality rates amongst the high
and the low income group countries signifies a health inequity [1].
Further, there exists a higher prevalence in the low socio-economic
groups within different countries, which exemplifies uneven
availability and accessibility to the health services [2].
Situation
The age-adjusted incidence of cervical cancer in India is 25.9%
(1, 34,420 incident cases), which is higher than the average for
South East Asian region [3]. According to the Population Based
Cancer Registries (PBCR), it has the second highest prevalence
following breast cancer [4]. The pervasiveness of cervical cancer is
much higher in rural and low socioeconomic groups in India [2,5].
Lack of access to screening, affordability, compliance and follow
up of treatment are the major causes for this pattern of
discordance [6].
Economic Burden in India
In addition to the significant contribution to the mortality rates,
cervical cancer also leads to the loss of productive life due to
prolonged disability [1]. It contributes to considerable economic
burden, as the women of age group 25 - 64 years tend to be the
sole caretakers of their families and households; and in some cases,
they as well contribute to the family income [7]. Additionally, they
are further deprived due to high medical costs, especially since
most of the cases in developing countries are diagnosed at later
stages,when the treatment is costly combined with poor prognosis
[8]. Accordingly, there is a need to prevent the soaring secondary
costs and economic burden as the more cost effective treatment
modality can effect the outcome of patient’s post treatment quality
of life.
The current study compares the scores of pre-treatment and
post-treatment quality of life. The quality of life has been
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documented to vary with the treatment, the time since diagnosis
and the cancer site [9]. Additionally, there are cultural differences
which affect the quality of life assessment perception, as there are
dissimilar beliefs regarding the constituents of normality and
disease [10]. Being diagnosed with the disease is associated with
social stigma, due to the belief that it is caused by sexual
promiscuity, poor hygiene and the use of oral contraceptives [11].
Given that these beliefs are different from the Western world,
therefore, reasonably there should be differences in the perception
of quality of life in India. Thus, we conducted the study in patient
population of north India and determined whether there is any
significant difference in the post treatment quality of life.
Furthermore, we structured a prediction model based on the
findings of our study, which would serve to forecast the quality of
life.
Materials and Methods
Ethics Statement
Institutional approval was obtained after reviewing the study
protocol by the Institutional Review Board of the Himalayan
Institute of Medical Sciences and Research, Uttarkhand. Written
informed consent were obtained from patients after clear and
concise explanation about the study. All the women in this study
were informed about the right to refrain from participation in the
study without any affect on the quality of health care services being
provided to them. Patient confidentiality was assured by coding
the patients’ information and removing the identifiable personal
data before the data analysis.
Study Population
All patients who had undergone surgical treatment for cervical
cancer between April, 2007 to March, 2011 at the tertiary care
academic hospital, Himalayan Institute of Medical Sciences and
Research, Uttarkhand in Northern India were selected for this
study. Of the 361 patients who gave completely filled the consent
form, 108 were excluded due to non-availability of post treatment
assessment data. 55 subjects were excluded due to accompanying
psychiatric disease, cognitive impairment, diagnosis of multiple
cancers, ambiguity in determining follow-up time or incomplete
information, and Stage IV of cancer. After exclusion, 198 subjects
with cervical cancer were included in the study group.
Measures and Instruments
The patients were interviewed using two structured question-
naires-Health Related Quality of Life (HRQoL) questionnaires
(EORTC QLQ C-30 and CX-24), to collect information about
socio-economic and clinical status. The baseline values were
recorded when the patient first reported to the hospital (T1) and
second evaluation was done at a follow-up visit 6 months post
treatment (T2). Clinical evaluation was performed at the same
time points and relevant information was documented.
The European Organisation for Research and Treatment of
Cancer (EORTC)- general cancer quality of life score question-
naire (QLQ C-30, and its cervical cancer module (QLQ CX-24)
were used to measure HRQoL. These questionnaires have been
extensively tested in multicultural and multidisciplinary settings,
and have been confirmed to be reliable and valid [12–14]. The
EORTC QLQ C-30 questionnaire comprises of 30 questions
which assess functioning (physical, role, cognitive, emotional,
social) and symptoms (fatigue, nausea and vomiting, pain,
dyspnea, insomnia, appetite loss, constipation, diarrhea, financial
difficulty), and a global health status score which assesses the
overall QOL. The EORTC QLQ CX-24 questionnaire consists of
24 questions assessing functioning (body image, sexual enjoyment,
sexual/vaginal functioning) and symptoms (symptoms experience,
lymphoedema, peripheral neuropathy, menopausal symptoms,
sexual worry). Both questionnaires use a four-point response scale
(not at all, a little, quite a bit, and very much) to assess each
functional or symptom item, and a seven-point response scale is
used to assess global health status (from very poor to excellent). For
model development the categorical raw scores were linearly
transformed into a score of 0 - 100 for processing according to the
EORTC manual [15].
Systemic literature review, established clinical knowledge and
by performing univariate linear regression analysis following
features were found to be statistically significant (pv0:05) and
were used in the development of the prediction model: age, marital
status, vaginal bleeding, vaginal discharge, dyspareunia, abdom-
inal pain, weight loss, parity, difficulty in controlling bowels or
emptying bladder, cervical cancer stage, treatment, lymphoedema
and peripheral neuropathy.
Prediction Model Development
For the development of the prediction model we compared the
performance of 4 different algorithms. Support Vector Machi-
nes(SVM) was utilized with two different kernels- Linear and
Radial Basis Function(RBF), Artificial Neural Network(ANN) and
regularized Logistic Regression(LR). The preprocessing of the
dataset was performed to standardize and normalize the features
before applying learning algorithms. The quality of life question-
naire mean results were obtained in continuous data format on a
scale of 0 - 100, which was converted into discrete 3 class output
for each scale, to train the classifier machine learning algorithms
(See Appendix S1). All the 13 variables were provided to the
models and trained separately for functional, symptom and global
health/QoL scales. The Scikits-Learn module in Python pro-
gramming language was utilized for the development of Logistic
Regression and SVM models [16]. The ANN multilayer
perceptron(MLP) was developed using PyBrain module in Python
[17].
Prediction Model Validation and Comparison
Cross-validation method with stratified K-Fold iterator was
employed to derive a reliable estimate of the performance. Cross-
validation approach splits the whole data several consecutive times
in different train and test set, and returns the averaged value of the
prediction scores. Stratified K-Fold return group of samples, called
‘‘folds’’ by preserving the same percentage for each target class as
in the complete set. The stratified 6-folds were implemented to
estimate the accuracy. Predicted values were then combined across
the 6 runs and summarised by mean Area Under Curve(AUC).
The mean accuracy, mean area under the curve (AUC),mean
squared error (MSE) and adjusted-for-chance mutual information
index (AMI) of each of the models were calculated for
performance comparison between the Logistic Regression, SVM
(‘Linear’), SVM (‘RBF’) and ANN models. An individual cervical
cancer patient was the unit of analysis in this study. The area
under the ROC (Receiver Operating Characteristics) curve or
simply AUC has been validated to evaluate the ranking
performance of the machine learning algorithms [18]. The
MSE, which is computed as difference between the true and
predicted values and then averaged across data, was used as an
indicator of effectiveness with model fits [19]. Adjusted Mutual
Information (AMI) is an adjustment of the Mutual Information
(MI) score to account for chance [20](See Appendix S1).
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Statistical Analysis
We used R, an open source statistical programming environ-
ment for univariate linear regression analysis; and scientific
computing Python packages to generate logistic regression, SVM
and ANN models. [16,17,21,22]. The student’s t test or x2 test was
utilized for comparing the characteristics in the study population
and the quality of life scales before and after treatment (p§0:05).
Results
The clinical and demographic characteristics of the participant
cervical cancer patients are listed in Table 1. The quality of life of
cervical cancer patients in the functioning scales comprising
physical, emotional and social functioning were statistically
significant post treatment. Furthermore, the global health/QoL
improvement was statistically significant, while cognitive function-
ing was not substantial as presented in Table 2. The mean score of
global health of cervical cancer patients post treatment was 77.90,
which was significantly higher than pre treatment values 54.32 by
about 23.58 points. The symptom scales items- ‘‘fatigue’’ and
‘‘nausea/vomiting’’ improved but the symptom ‘‘pain’’ was
aggravated. Post treatment single item scales items- ‘‘dyspnoea’’,
‘‘insomnia’’, ‘‘appetite loss’’ and ‘‘constipation’’ were lower, while
the item - financial difficulties was elevated in comparison to pre
treatment scores. Table 3 represents cervical cancer specific
EORTC QLQ CX-24 module scores for cervical cancer patients
pre and post treatment. The patient experienced enhanced body
image, however sexual functions like sexual activity and sexual/
vaginal functioning were decreased. Symptoms experience-
‘‘lymphedema’’, ‘‘peripheral neuropathy’’, ‘‘menopausal symp-
toms’’ and ‘‘sexual worry’’ of the patients aggravated variably post
treatment. Mean symptoms experience score post-treatment was
21.69, with an aggravation of 7.32 compared to pre-treatment
scores. The patients experienced substantial decrease in sexual
activity functioning with post-treatment mean score of 11.52
compared to 24.17 pre-treatment.
Predictive Factors Significance
The significance of the predictive factors previously selected
using univariate linear regression analysis were compared. Table 4
shows the coefficients of significant variables for Symptom scale,
Functional scale and Global health/Quality of Life (GH/QoL)
post treatment in the logistic regression model. All the selected
variables were found to be statistically significant (pv0:05).
Comparison of Prediction Models
Table 1 shows the performance comparison of four machine
learning algorithms on Symptom, Global health/QoL and
Functional scales for the prediction of post-treatment cervical
cancer quality of life outcomes. This has been demonstrated in
terms of Mean Squared Error (MSE), mean Area Under Curve
(AUC), Adjusted for chance Mutual Information index (AMI) and
accuracy for prediction.
Symptom scale. Comparison of the four models reveal, that
all the models performed suitably on the Symptom scale. On the
basis of accuracy, 3 models Support Vector Machine with Linear
kernel-SVM (Linear), Support Vector Machine with Radial Basis
Function-SVM (RBF) and LR (Logistic Regression) scoredw90%;
and SVM (Linear) outperformed other models with accuracy of
97:37%. In terms of mean AUC, SVM (Linear) and Artificial
Neural Network (ANN) surpassed SVM (RBF) and LR (mean
AUC=0.90, 0.85, 0.80 and 0.72, respectively). The mean squared
error (MSE) was low for all four models varying between
0.02{0.03. SVM (Linear) was superior to other models SVM
(RBF), LR and ANN in terms of AMI (AMI= 0.90, 0.81, 0.82 and
0.82, respectively). (Table 5, Figure 1A).
Global Health/QoL scale. On Global Health/QoL scale
SVM(Linear) was better than the other models in all the four
parameters (MSE, Mean AUC, AMI and Accuracy equal to 0.07,
0.84, 0.79 and 95.26%, respectively). While SVM (RBF) was
better than LR and ANN on all parameters except AMI (MSE,
Mean AUC, AMI and Accuracy%=0.08, 0.80, 0.20 and 93.12,
respectively). In case of LR mean AUC (0.64) suffered, while ANN
performed average (MSE, Mean AUC, AMI and Accura-
cy%=0.08, 0.73, 0.65 and 74.38, respectively). On Global
Health/QoL scale, performance of all the models suffered
compared to other scales. (Table 5, Figure 1B).
Functional scale. The Functional scale SVM (RBF) did
better than others on all parameters except MSE (MSE, Mean
Table 1. Demographic and clinical characteristics of the
patient cohort*.
Variables N(%)
Age (years) 50.9610.4
Education No education 74(37.4)
Less than High School 77(38.9)
High school and above 47(23.8)
Marital Status Married/Cohabiting 179(90.4)
Not Married 19(9.6)
Menopausal Status Premenopausal 63(31.8)
Postmenopausal 135(68.2)
Parity Nullipara 32(16.7)
Primipara 92(46.5)
Multipara 74(36.8)
Abdominal Mass No 172(86.7)
Yes 26(13.1)
Staging(FIGO){ Stage IA1 3(1.5)
Stage IA2 11(5.6)
Stage IB1 53(26.8)
Stage IB2 21(10.6)
Stage IIA1 26(13.1)
Stage IIA2 21(10.6)
Stage IIB 27(13.6)
Stage IIIA 13(6.5)
Stage IIIB 26(13.1)
Cell Type Squamous cell carcinoma 147(74.2)
Adenocarcinoma 31(15.7)
Adenosquamous cell carcinoma 6(3.0)
Other types 14(7.1)
Treatment Modality` Conization 3(1.5)
Total Abdominal Hysterectomy 8(4.0)
Radical Hysterectomy 76(38.4)
Chemotherapy 9(4.6)
Wertheim’s Hysterectomy 46(23.2)
Radiochemotherapy 59(29.8)
*Values are means 6 standard deviations.
{FIGO, International Federation of Gynecology and Obstetrics.
`Some patients received multiple treatment interventions.
doi:10.1371/journal.pone.0089851.t001
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AUC, AMI and Accuracy%=0.26, 0.90, 0.78 and 97.32,
respectively). While SVM(Linear) sustained it’s performance on
Functional scale as well (MSE, Mean AUC, AMI and Accura-
cy%=0.13, 0.85, 0.77 and 95.81, respectively). ANN was better
than LR except on Accuracy% (MSE, Mean AUC, AMI and
Accuracy%=0.13, 0.83, 0.90 and 71.28 and 0.16, 0.60, 0.34 and
93.12, respectively) (Table 5, Figure 1C).
As SVM (Linear) performed consistently on all the 3 functional
scales, we utilized it in developing prediction model.
Discussion
Our study compares the pre-treatment and the post-treatment
HRQoL for cervical cancer patients in north India. Various
factors are responsible for the changes in the quality of life of the
women diagnosed with gynaecological cancer. During pelvic
surgery, there is functional damage and removal of parts of the
female genital tract. Additionally, radiation damages the vaginal
mucosa and epithelium. Moreover, there are other side effects of
radiotherapy such as nausea, vomiting, diarrhoea, constipation,
mucositis, weight changes and hormonal changes [23].
For patients with disease of limited volume, radical abdominal
hysterectomy is preferred, which impairs the quality of life due to
physiological and psychological effects [24]. In the current study, it
was found that the most common treatment modality opted was
radical hysterectomy followed by, Wertheims hysterectomy and
radio-chemotherapy. Almost 25% of the patients with early stage
cancer reported post surgery changes in vagina that lasted for 5
years [24]. The concomitant radio-chemotherapy is responsible
for doubling the acute and late toxicities [25].
The psychological impact is an essential parameter, as it
determines the self perceived changes in the quality of life which
are assessed. There was a preponderance of married or cohabiting
women, while the non-married women constituted a small
proportion of the affected population. Although, it may be held
responsible for being a risk factor however, marital status has been
found to be a predictive factor in ‘‘concerns’’ domain, which
demonstrates that the presence of a partner provides emotional
support for the patients [26]. It is suggested that the health
professionals should give more importance to the role of family
and spouse while quantifying the quality of life [26].
The Global Health Status showed a highly significant increase
after the treatment making it obvious that quality of life improves
after the treatment. Among the Functional Scales all the items
confirmed a significant increase within 6 months, namely physical,
role, emotional, cognitive and social functioning. This was in
contrast to a study which revealed that the Global QOL,
emotional and role functioning remained low even after 1 year
of the completion of the treatment [27]. Nevertheless, role and
social functioning illustrated a highly significant rise post
treatment. This implies that the survivors perceived an enhance-
ment in their public and civil roles and find a definitive
improvement post-treatment in this regard.
The Symptom scale analysis revealed that there was a
significant decrease in ‘‘fatigue’’ and ‘‘nausea/vomiting’’. Howev-
er, there was a highly significant rise in post-treatment ‘‘pain’’.
Amongst the items of Single Item Scale- ‘‘Appetite loss’’ decreased
significantly. In contrast, in an another study using EORTC QLQ
C-30 [28], the ‘‘level of nausea/vomiting’’, ‘‘pain’’ and ‘‘appetite
loss’’ were increased. In addition, there was an increase in post-
treatment diarrhoea, however constipation decreased. Radiother-
apy has been documented to be associated with diarrhoea while
constipation is attributed to injury to the parasympathetic nerves
during pelvic surgery [28,29]. These findings may be affected by
the relative number of patients receiving different treatment
modalities and the individual differences in response to the
therapies. A highly significant reduction in insomnia was depicted
Table 2. Comparative pre and post treatment EORTC QLQ C-
30 Quality of Life scores in cervical cancer women.
EORTC QLQ C-30
Scale
Pre
Treatment
Post
Treatment P-Value*
Global Health
Status/Qol scale
Global Health Status/Qol 54.32(9.65) 77.90(7.17) v0:001
Functional Scale
Physical functioning 69.86(10.73) 80.60(27.06) 0:018
Role Functioning 69.06(16.68) 80.37(15.16) v0:001
Emotional Functioning 60.20(16.37) 77.13(14.15) v0:001
Cognitive Functioning 71.06(16.68) 73.39(18.36) 0:039
Social Functioning 60.67(11.57) 68.26(16.78) v0:001
Symptom scales/Items
Fatigue 38.21(11.15) 24.88(7.32) 0:056
Nausea and Vomiting 12.01(11.30) 2.00(5.52) 0:049
Pain 19.67(18.32) 22.66(6.23) v0:001
Single Item scales
Dyspnoea 26.52(21.51) 10.56(15.86) 0:098
Insomnia 29.67(18.84) 22.30(24.12) v0:001
Appetite loss 33.98(17.67) 31.20(8.36) 0:053
Constipation 33.43(20.60) 25.87(10.04) 0:201
Diarrhoea1 3.87(9.67) 8.67(12.25) 0:064
Financial Difficulties 34.67(28.62) 46.34(19.71) v0:001
*P values are comparisons between groups with x2 or student’s t test.
Higher scores in the functioning and global health status scales represented
better functioning and QOL, whereas higher scores in the symptom scales
indicated greater problems.
doi:10.1371/journal.pone.0089851.t002
Table 3. EORTC QLQ CX-24 cervical cancer module scores in
cervical cancer woman pre and post treatment.
EORTC QLQ CX-24
Scale
Pre
Treatment
Post
Treatment P-Value*
Functional Scale
Body Image 18.36(15.32) 27.81(08.43) v0:001
Sexual activity 18.54(18.67) 12.27(10.67) 0:032
Sexual enjoyment 29.56(12.89) 10.33(06.81) v0:001
Sexual/vaginal functioning 24.42(8.98) 11.98(7.76) v0:001
Symptoms Scale
Symptoms experience 15.44(12.23) 28.65(17.42) 0:027
Lymphoedema 1.33(6.54) 13.87(19.24) v0:001
Peripheral neuropathy 4.33(6.47) 13.33(19.24) 0:028
Menopausal symptoms 9.33(15.27) 34.67(22.52) v0:001
Sexual worry 14.66(16.88) 33.43(25.46) v0:001
*P values are comparisons between groups with x2 or student’s t test.
Higher scores in the functioning and global health status scales represented
better functioning and QOL, whereas higher scores in the symptom scales
indicated greater problems.
doi:10.1371/journal.pone.0089851.t003
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post-treatment. This may imply a reduction in the anxiety
regarding the course of cancer. Conversely, the ‘‘financial
difficulties’’ increased in a highly significant proportion of the
survivors. Cervical cancer patients have shown to have significant
difficulties with the finances [30]. This bears a specific relevance in
developing countries, where the economic burden is a significant
factor affecting the quality of life. Our study revealed that the
survivors had a worse ‘‘body image’’ as compared to pre-
treatment, this probably is a consequence of the cancer experience
or the treatment as reported in the EORTC QLQ CX-24 scale.
Sexuality is an important aspect of gynaecological cancer, thus
being a crucial determinant of the quality of life. The survivors
have intimacy issues and are unacquainted so as how to recreate
the intimate side of the relationship with their spouse. They have a
constant fear of recurrence, combined with the grief of never
having a child once diagnosed [31]. There was a significant
decrease in ‘‘sexual activity’’, along with a highly significant
decrement in ‘‘sexual and vaginal functioning’’ score in our study.
This is supported by the previous study which stated that
approximately 40% to 100% individuals face sexual dysfunction
after diagnosis and treatment. The reason behind the same is, that
cervical cancer and its treatment affects the same areas of the body
which are involved with sexual response [30]. It is well
documented that both chemotherapy and radiotherapy are
associated with sexual problems like dyspareunia, anxiety about
sexual performance and insufficient lubrication [30]. Additionally,
chemotherapy side effects, like nausea and fatigue may also reduce
sexual functioning [32]. Various studies reinforce that the women
who undergo surgery and receive radiotherapy as well have the
worse sexual problems, as opposed to the women who are treated
by surgery alone [33,34]. This signifies that the patient, regardless
of their treatment modality, should be counselled prior and post-
treatment. Moreover, the treatment modality selection is of
primary essence, so as to avoid the need of adjuvant radiotherapy
after surgery.
The survivors also reported a highly significant rise in the
‘‘menopausal symptoms’’. These menopausal symptoms were
worse for the women with radiation therapy, as supported by a
previous study stating more aggressive menopausal symptoms
when patients are rendered menopausal by surgical oophorectomy
as compared to those made climacteric by radiation therapy [35].
The Symptom Scale EORTC QLQ CX-24, revealed that there
was a significant increase in ‘‘lymphoedema’’ and ‘‘peripheral
neuropathy’’. Lymphoedema may be attributed to lymph node
damage by metastases. The significant increase in the peripheral
neuropathy can be explained on the basis of post-radiation
increase in the neurotoxicity [36].
The highly significant rise in the ‘‘sexual worry’’ item of the
symptom scale is similar to the study, where the sexual worries
were reported to be more than that of the control group. Our
study analyzed the post-treatment quality of life which is
noteworthy, as the time period chosen was 6 months post-
treatment. This period is of great significance, as it is the time
when the women cope up with the difficulties arising from the
treatment and take over their responsibilities [37]. In the Indian
context, it implies almost all the household chores and for most of
the women even the financial responsibilities. Apart from these
factors, the women who have recovered, fear recurrence.
Development of Prediction Model
Based on these findings, we developed a prediction model tool
for estimating the post treatment HRQoL outcome on Functional,
Symptom and Global Health/QoL scales. During the develop-
ment of the model, we compared the well established four machine
learning algorithms, among which SVM(Linear) proved to be most
accurate and consistent. To the best of our knowledge, this study is
the first one to develop a prediction model for the post-treatment
QoL. It also depicts that, given the same clinical and socio-
demographic inputs; and output target classes, the predictive
accuracy of SVM(Linear) is the highest and most consistent for
HRQoL scales.
Recently, SVM and ANN models have been used for non-linear
modelling in diverse fields, ranging from bioinformatics [38–40],
neurosciences [41,42], imaging [43,44] to clinical prediction
model development [45,46].
We implemented univariate linear regression analysis during
feature selection stage and validated our features by logistic
regression coefficients values. Logistic regression was prioritized
Table 4. Coefficients(coef) of significant variables for Symptom scale, Functional scale and Global health/Quality of Life (GH/QoL)
post treatment in Logistic Regression model, a Generalized linear model (GLM) type.
Symptom Scale Functional Scale Global Health Scale
Variables Coef P value Coef P value Coef P value
Age 1.1024 0:003 20.2036 v0:001 21.1019 0:002
Marital Status 0.6136 0:008 1.1539 0:007 0.2683 v0:001
Vaginal Bleeding 2.1313 v0:001 1.6091 0:002 3.0775 0:006
Vaginal Discharge 1.1313 v0:001 0.4091 0:001 1.0876 0:046
Dyspareunia 0.1223 0:019 0.4415 0:015 1.0322 0:004
Abdominal Pain 2.3022 v0:001 21.1075 0:006 22.1603 0:002
Weight Loss 0.1813 0:001 20.2069 v0:001 22.2733 v0:001
Parity 20.1479 v0:001 21.0481 0:002 21.0221 0:006
Bowel and Bladder control 3.0422 v0:001 22.075 0:002 21.0603 0:002
FIGO staging 3.2438 0:001 3.3078 v0:001 4.0627 v0:001
Treatment given 1.3407 0:032 24.0788 0:001 23.3527 v0:001
Lymphoedema 2.1813 v0:001 21.2069 v0:001 20.27733 v0:001
Peripheral Neuropathy 1.2561 0:001 21.3315 v0:001 20.3511 v0:001
doi:10.1371/journal.pone.0089851.t004
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over linear regression due to multi-class nature of the classification.
Cross validation with stratified K-Fold method was implemented
to rule out varying percent of target class in a test set. This practice
prevented biased predictions, over-fitting and hence provided with
the accurate cross validation scores. We utilized AMI rather than
Normalized Mutual Information index (NMI), as NMI fails to
account for chance in comparing clustering performances by
supervised learning algorithms [20] (See Appendix S1). The
prediction model aims to determine the quality of life in an Indian
context, which is essentially different from the developed countries
in terms of socio-sexual environment and financial context which
have been important determinants, as found in the study.
Online Tool
We developed an online tool PrediQt-Cx, utilizing our
prediction model, which is available at http://prediqt.org. The
web application was developed using Python modules and back-
end implementation of SVM (Linear) algorithm. The aim of
developing the web application was to facilitate the accessibility of
prediction model for critical evaluation, utilization for supporting
treatment decisions and for external validation.
Limitations
Our study was limited to north Indian population only. Thus,
the applicability of model will be limited until external validation
in cross-cultural and diverse socioeconomic settings is undertaken.
Despite the multiple options being provided as treatment modality,
the training of models and predictions were based only on three
alternative sets of models (surgical treatment modalities, radio-
chemotherapy and multiple interventions). This was decided as the
sample sizes for some treatment modalities (conization, total
abdominal hysterectomy and chemotherapy) were small and
model training on them was not possible without prediction bias.
Similarly FIGO (International Federation of Gynaecology and
Obstetrics) stages were clubbed together into four groups.
Grouping was based on stage specific clinical treatment decisions
Figure 1. Mean Area Under Receiver Operating Characteristic
(ROC) curve. Mean ROC (AUC) for Support Vector Machine algorithm
with Linear Kernel for (A) Prediction of Symptom scale was 0.90. (B)
Prediction of Global Health/QoL was 0.84. (C) Prediction of Functional
scale was 0.85.
doi:10.1371/journal.pone.0089851.g001
Table 5. The performance comparison of four machine
learning algorithms on symptom, global health/QoL and
functional scales for the prediction of post treatment cervical
cancer quality of life outcomes.
Scale MSE Mean AUC AMI Accuracy %
Symptom Scale
SVM(Linear) 0.02 0.90 0.92 97.37
SVM(RBF) 0.03 0.80 0.81 94.58
LR 0.02 0.72 0.82 94.34
ANN 0.03 0.85 0.82 87.56
Global Health/QoL
SVM(Linear) 0.07 0.84 0.79 95.26
SVM(RBF) 0.08 0.80 0.20 93.12
LR 0.13 0.64 0.59 89.29
ANN 0.08 0.73 0.65 74.38
Functional Scale
SVM(Linear) 0.13 0.85 0.77 95.81
SVM(RBF) 0.26 0.90 0.78 97.32
LR 0.16 0.60 0.34 93.12
ANN 0.13 0.83 0.90 71.28
MSE =Mean Squared Error, AUC =Mean Area Under ROC(Receiver Operating
Characteristics) Curve, AMI = Adjusted-for-chance Mutual Information Index,
SVM(Linear) = Support Vector Machine with Linear Kernel, SVM(RBF) = Support
Vector Machine with Radial Basis Function Kernel, LR = Logistic Regression,
ANN=Artificial Neural Network.
doi:10.1371/journal.pone.0089851.t005
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to account for small sample sizes in some stages (Stage IA1 and
Stage IA2).
Conclusion
In this study, the prediction model PrediQt-Cx, which was
based on SVM, was developed and internally cross validated. After
external validation, PrediQt-Cx can be employed in decision
making procedure by clinicians and patients from north India
region. It has been made available for open access at http://
prediqt.org.
Supporting Information
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(PDF)
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